Granulomatosis with polyangiitis, complicated by ocular adnexa lesion and vascular changes in retina and choroid (literature review with a clinical case)

Granulomatosis with polyangiitis (GPA) is manifested as ocular pathology in almost a third of patients, which can either be detected at the onset of the disease or occur in the late stages. The pathological process involves the orbit, sclera, episclera, cornea, conjunctiva, eyelids, nasolacrimal system, optic nerve, retina and choroid. Lesion of eye and its surrounding structures determines the severity of the pathological process, the patient’s quality of life and prognosis. The article presents a clinical case of a 38-year-old man with an unfavorable course of GPA, lesion to upper and lower respiratory tract, kidneys, and musculoskeletal system. The authors consider ocular manifestations in the context of a systemic disease. An ophthalmological examination of the patient revealed changes in sclera and choroid, which had not previously been described in detail in the literature. The patient underwent cataract phacoemulsification in the right eye with implantation of a posterior chamber intraocular lens. The dynamics of clinical manifestations of eye lesion in the near future is positive, but in the long term it remains doubtful due to pronounced changes in the orbit and adnexa of the eye against the background of ongoing small vessels vasculitis. Early consultation with an ophthalmologist and optical coherence tomography in patients with GPA are necessary at any stage of the disease. The clinical case is presented with consideration to the CARE 2021 recommendations.

1. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCAassociated vasculitis. Rheum Dis Clin North Am. 2010; 36(3): 447-461. doi: 10.1016/j.rdc.2010.04.002

2. Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): Clinical aspects and treatment. Autoimmun Rev. 2014; 13(11): 1121-1125. doi: 10.1016/j.autrev.2014.08.017

3. Zlobina TL, Osiook NV, Yakubovich AI, Kalyagin AN, Yanysheva AV, Skvortsova EN. Kaposi’s sarcoma associated with Wegener’s granulomatosi. Rheumatology Science and Practice. 2004; 42(1): 92-93. (In Russ.). doi: 10.14412/19954484-2004-1394

4. Yakubovich AI, Zlobina TI, Kalyagin AN, Osipok NV, Yanysheva AV, Skvortsova EN, et al. A case of immunosuppressive Kaposi’s sarcoma in a patient with Wegener’s granulomatosis.russian Journal of Clinical Dermatology and Venereology. 2005; 3(1): 11-14. (In Russ.).

5. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3): 221-232. doi: 10.1056/NEJMoa0909905

6. You C, Ma L, Lasave AF, Foster CS. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener’s). Ocul Immunol Inflamm. 2018; 26(8): 1166-1173. doi: 10.1080/09273948.2017.1327602

7. Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019; 61(1): 44-50. doi: 10.1159/000486791

8. Recillas-Gispert C, Serna-Ojeda JC, Flores-Suárez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s). Graefes Arch Clin Exp Ophthalmol. 2015; 253(12): 2279-2284. doi: 10.1007/s00417-015-3198-5

9. Padoan R, Campaniello D, Gatto M, Schiavon F, Doria A. Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis. Autoimmun Rev. 2022; 21(3): 103018. doi: 10.1016/j.autrev.2021.103018

10. Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015; 122(6): 1262-1268. doi: 10.1016/j.ophtha.2015.01.016

11. Dammacco R, Biswas J, Mohanan-Earatt A, Lisch W, Zito FA, Rubini G, et al. The eye is a common site of granulomatosis with polyangiitis. A collaborative study. BMC Ophthalmol. 2023; 23(1): 26. doi: 10.1186/s12886-022-02743-x

12. Gottenberg JE, Mahr A, Pagnoux C, Cohen P, Mouthon L, Guillevin L, et al. Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. La Presse Médicale. 2007; 36(5): 771-778..

13. Dadonienė J, Pileckytė M, Baranauskaitė A, Kirdaitė G. Clinical characteristics and long-term outcomes of 35 patients with Wegener’s granulomatosis followed up at two rheumatology centers in Lithuania. Medicina. 2010; 46(4): 256.

14. Yang MK, Kim HW, Kang EH, Kim N, Choung H, Khwarg SI. Ophthalmic manifestations and visual outcomes of granulomatosis with polyangiitis: A retrospective multicentre study in Korea. Eye (Lond). 2023; 37(7): 1302-1307. doi: 10.1038/s41433-022-02114-2

15. Kubaisi B, Abu Samra K, Foster CS. Granulomatosis with polyangiitis (Wegener’s disease): An updated review of ocular disease manifestations. Intractable Rare Dis Res. 2016; 5(2): 61-69. doi: 10.5582/irdr.2016.01014

16. Perumal B, Black EH, Levin F, Servat JJ. Non-infectious orbital vasculitides. Eye (Lond). 2012; 26(5): 630-639. doi: 10.1038/eye.2012.28

17. Novikov PI, Moiseev SV, Kuznetsova YeI, Semenkova EN, Mukhin NA. Changes in the course of the disease and the prognosis of granulomatosis with polyangiitis (Wegener’s): The results of a 40-year follow-up. Clinical Pharmacology and Therapy. 2014; 1: 32–37. (In Russ.).

18. Tan LT, Davagnanam I, Isa H, Taylor SR, Rose GE, Verity DH, et al. Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement. Ophthalmology. 2014; 121(6): 1304-1309. doi: 10.1016/j.ophtha.2013.12.003

19. Harper SL, Letko E, Samson CM, Zafirakis P, Sangwan V, Nguyen Q, et al. Wegener’s granulomatosis: The relationship between ocular and systemic disease. J Rheumatol. 2001; 28(5): 1025-1032.

20. Beketova TV. Granulomatosis with polyangiitis, which is pathogenetically associated with antineutrophil cytoplasmic antibodies: Clinical features. Rheumatology Science and Practice. 2012; 50(6): 19-28. (In Russ.). doi: 10.14412/1995-4484-2012-1288

21. Karnakova MV, Kalyagin AN, Antipova OV, Vitvitskaya KB, Radnayeva YeE. Modern pharmacotherapy for granulomatosis with polyangiitis. Effective Pharmacotherapy. 2023; 19(29): 22-27. (In Russ.). doi: 10.33978/2307-3586-2023-19-29-22-26

22. Yaseen K, Mandell BF. ANCA associated vasculitis (AAV): A review for internists. Postgrad Med. 2023; 135(Suppl 1): 3-13. doi: 10.1080/00325481.2022.2102368

23. Ungprasert P, Crowson CS, Cartin-Ceba R, Garrity JA, Smith WM, Specks U, et al. Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study. Rheumatology (Oxford). 2017; 56(10): 1763-1770. doi: 10.1093/rheumatology/kex261

24. Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A, et al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016; 29(2): 151-159. doi: 10.1177/0394632015617063

25. Andrada-Elena M, Ioana TT, Mihaela FM, Irina-Elena C, Andrei TI, Florian B. Wegener’s granulomatosis with orbital involvement: Case report and literature review. Rom J Ophthalmol. 2021; 65(1): 93-97. doi: 10.22336/rjo.2021.19

26. Maqbool U, Maqbool A, Maqbool A, Qadeer A, Mehmood MF, Loon M. An atypical presentation of granulomatosis with polyangiitis: A case report. Radiol Case Rep. 2023; 18(6): 22452248. doi: 10.1016/j.radcr.2023.03.023

27. Kamali S, Erer B, Artim-Esen B, Gul A, Ocal L, Konice M, et al. Predictors of damage and survival in patients with Wegener’s granulomatosis: Analysis of 50 patients. J Rheumatol. 2010; 37(2): 374-378. doi: 10.3899/jrheum.090387

28. Kopaev VG (ed.). Eye diseases: Textbook for students of medical universities. Moscow: Meditsina; 2002. (In Russ.).

29. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with sweptsource optical coherence tomography. Retina. 2016; 36(3): 499-516. doi: 10.1097/IAE.0000000000000742

30. Gal-Or O, Dansingani KK, Sebrow D, Dolz-Marco R, Freund KB. Inner choroidal flow signal attenuation in pachychoroid disease: Optical coherence tomography angiography. Retina. 2018; 38(10): 1984-1992. doi: 10.1097/IAE.0000000000002051

31. Marc RE, Jones BW, Watt CB, Strettoi E. Neural remodeling in retinal degeneration. Prog Retin Eye Res. 2003; 22(5): 607-655. doi: 10.1016/s1350-9462(03)00039-9

32. Léveillard T, Sahel JA. Metabolic and redox signaling in the retina. Cell Mol Life Sci. 2017; 74(20): 3649-3665. doi: 10.1007/s00018-016-2318-7

33. Castanos MV, Zhou DB, Linderman RE, Allison R, Milman T, Carroll J, et al. Imaging of macrophage-like cells in living human retina using clinical OCT. Invest Ophthalmol Vis Sci. 2020; 61(6): 48. doi: 10.1167/iovs.61.6.48

34. Stolarz AJ, Mu S, Zhang H, Fouda AY, Rusch NJ, Ding Z. Opinion: Endothelial cells – macrophage-like gatekeepers? Front Immunol. 2022; 13: 902945. doi: 10.3389/fimmu.2022.902945